Payment overview · 2025
General Payments
$399.99
29 reported records · 5 companies
Healthcare provider profile · identity verified
Christa K. Dowell, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MCDANIELS, KY · NPI 1841509601
Verified facts
What the public records show
CMS Open Payments records show Christa K. Dowell, APRN received $399.99 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 67.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $268.03 | 67.0% | 21 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.09 | 11.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.30 | 8.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.27 | 7.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.30 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $399.99 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $171.47 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $96.56 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.56 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $44.09 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $34.30 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 319 | 74 |
| Gabapentin | Gabapentin | 314 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 85 |
| Lisinopril | Lisinopril | 298 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 72 |
| Potassium Chloride | Potassium Chloride | 253 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 251 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 57 |
| Metformin Hcl | Metformin Hcl | 235 | 47 |
| Omeprazole | Omeprazole | 230 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 224 | 57 |
| Furosemide | Furosemide | 205 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 40 |
| Meloxicam | Meloxicam | 168 | 49 |
| Losartan Potassium | Losartan Potassium | 162 | 37 |
| Montelukast Sodium | Montelukast Sodium | 158 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 24 |
| Jardiance | Empagliflozin | 125 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 116 | 21 |
| Sertraline Hcl | Sertraline Hcl | 105 | 26 |
| Buspirone Hcl | Buspirone Hcl | 102 | 23 |
| Ozempic | Semaglutide | 99 | 22 |
| Trazodone Hcl | Trazodone Hcl | 99 | 28 |
| Famotidine | Famotidine | 97 | 24 |
| Pregabalin | Pregabalin | 89 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 31 |
| Methylprednisolone | Methylprednisolone | 86 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 22 |
| Prednisone | Prednisone | 83 | 42 |
| Spironolactone | Spironolactone | 83 | 20 |
| Simvastatin | Simvastatin | 82 | 20 |
| Fluconazole | Fluconazole | 79 | 29 |
| Carvedilol | Carvedilol | 77 | 18 |
| Propranolol Hcl | Propranolol Hcl | 77 | 12 |
| Aripiprazole | Aripiprazole | 76 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 51 |
| Celecoxib | Celecoxib | 73 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 70 | 16 |
| Warfarin Sodium | Warfarin Sodium | 70 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 18 |
| Allopurinol | Allopurinol | 66 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 66 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 13 |
| Atenolol | Atenolol | 63 | 17 |
| Clonazepam | Clonazepam | 62 | 11 |
| Tramadol Hcl | Tramadol Hcl | 62 | 11 |
| Mounjaro | Tirzepatide | 61 | 12 |
| Ibuprofen | Ibuprofen | 56 | 16 |
| Sucralfate | Sucralfate | 56 | 15 |
| Baclofen | Baclofen | 55 | 15 |
| Memantine Hcl | Memantine Hcl | 55 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 15 |
| Valsartan | Valsartan | 49 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | suppressed |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 31 |
| Linzess | Linaclotide | 42 | 12 |
| Repatha Sureclick | Evolocumab | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 14 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Naproxen | Naproxen | 38 | 11 |
| Nystatin | Nystatin | 38 | 22 |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Vraylar | Cariprazine Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 28 |
| Azithromycin | Azithromycin | 37 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Topiramate | Topiramate | 36 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Eliquis | Apixaban | 31 | 12 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 15 |
| Nitroglycerin | Nitroglycerin | 29 | 17 |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Vilazodone Hcl | Vilazodone Hcl | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Colestipol Hcl | Colestipol Hcl | 21 | 11 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Topiramate Er | Topiramate | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $399.99 · 29 records | ABBVIE INC. | Auvelity, FANAPT, Kerendia, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error